Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
Type:
Grant
Filed:
April 18, 2014
Date of Patent:
February 9, 2016
Assignee:
RELIABLE BIOPHARMACEUTICAL CORPORATION
Inventors:
Sourena Nadji, James T. Smoot, Joseph A. Vanartsdalen
Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
March 24, 2015
Assignee:
Reliable Biopharmaceutical Corporation
Inventors:
Payal Parth Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
Type:
Application
Filed:
April 18, 2014
Publication date:
January 15, 2015
Applicant:
Reliable Biopharmaceutical Corporation
Inventors:
Sourena NADJI, James T. Smoot, Joseph A. Vanartsdalen
Abstract: This disclosure relates to an improved process for the preparation of regadenoson, pharmaceutically acceptable salts thereof, and hydrates thereof, and for the preparation of intermediates useful in the synthesis of regadenoson. The disclosure also relates to a new crystalline form of regadenoson. Processes for the preparation of the crystalline form, compositions containing the crystalline form, and methods of use thereof are also described.
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
October 14, 2014
Assignee:
Reliable Biopharmaceutical Corporation
Inventors:
Luzviminda T. Wooldridge, Chun Ma, Sourena Nadji
Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
Type:
Grant
Filed:
September 14, 2012
Date of Patent:
April 22, 2014
Assignee:
Reliable Biopharmaceutical Corporation
Inventors:
Sourena Nadji, James T. Smoot, Joseph A. Vanartsdalen
Abstract: This disclosure relates to an improved process for the preparation of regadenoson, pharmaceutically acceptable salts thereof, and hydrates thereof, and for the preparation of intermediates useful in the synthesis of regadenoson. The disclosure also relates to a new crystalline form of regadenoson. Processes for the preparation of the crystalline form, compositions containing the crystalline form, and methods of use thereof are also described.
Type:
Application
Filed:
April 26, 2012
Publication date:
February 13, 2014
Applicant:
Reliable Biopharmaceutical Corporation
Inventors:
Luzviminda T Wooldridge, Chun Ma, Sourena Nadji
Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
Type:
Application
Filed:
March 8, 2013
Publication date:
October 3, 2013
Applicant:
Reliable Biopharmaceutical Corporation
Inventors:
Payal Parth PATEL, Chun MA, Kevin K. OHRR, Sourena NADJI
Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
Type:
Application
Filed:
September 14, 2012
Publication date:
April 25, 2013
Applicant:
Reliable Biopharmaceutical Corporation
Inventors:
Sourena NADJI, James T. Smoot, Joseph A. Vanartsdalen
Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
Type:
Grant
Filed:
October 29, 2010
Date of Patent:
April 16, 2013
Assignee:
Reliable Biopharmaceutical Corporation
Inventors:
Payal Parth Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
Type:
Grant
Filed:
July 30, 2010
Date of Patent:
October 16, 2012
Assignee:
Reliable Biopharmaceutical Corporation
Inventors:
Sourena Nadji, James T. Smoot, Joseph A. Vanartsdalen
Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
Type:
Application
Filed:
October 29, 2010
Publication date:
May 10, 2012
Applicant:
Reliable Biopharmaceutical Corporation
Inventors:
Payal P. Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
Type:
Application
Filed:
July 30, 2010
Publication date:
May 5, 2011
Applicant:
Reliable Biopharmaceutical Corporation
Inventors:
Sourena Nadji, James T. Smoot, Joseph A. Vanartsdalen
Abstract: A novel, scaleable and improved process for preparing pentostatin and its analogs is disclosed. The method comprises the diastereospecific synthesis of the nucleobase from commercially available L-Dialkyl tartarates.
Type:
Grant
Filed:
December 12, 2003
Date of Patent:
July 1, 2008
Assignee:
Reliable Biopharmaceutical Corporation
Inventors:
Sourena Nadji, James Smoot, UmaShanker Sampath
Abstract: A sulfated acid amide having heparin-like properties of the formula:(R.sub.1)--NH--R--NH--(R.sub.1)where R.sub.1 is a di-, tri- or tetra-saccharide acid selected from cellobiose, cellotriose, cellotetrose, maltose, maltotriose and maltotetrose or mixtures thereof, and R is an alkylene of from 3 to 12 carbons, and is optionally substituted with one or more hydroxyls.
Abstract: A sulfated acid amide having heparin-like properties of the formula:(R.sub.1)--NH--R--NH--(R.sub.1)whereR.sub.1 is a di-, tri- or tetra-saccharide acid selected from cellobiose, cellotriose, cellotetrose, maltose, maltotriose and maltotetrose or mixtures thereof, andR is an alkylene of from 3 to 12 carbons, and is optionally substituted with one or more hydroxyls.